RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered Private Placement

RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered 
Private Placement 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: RepliCel Life Sciences Inc. 
OTCQB SYMBOL:  REPCF
TSX VENTURE SYMBOL:  RP 
MAY 9, 2014 
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered
Private Placement 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 9, 2014) -  
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN OR INTO
THE UNITED STATES 
RepliCel Life Sciences Inc. ("RepliCel" or the "Company")
(OTCQB:REPCF)(TSX VENTURE:RP) is pleased to announce it has completed the first
tranche of its financing announced on March 28, 2014, consisting of total units
(each a "Unit") of 3,717,167 at a price of $0.75 per Unit for total
gross proceeds of $2,787,875.25. The financing consisted of a brokered private
placement of 2,783,667 Units at a price of $0.75 per Unit for gross proceeds of
$2,087,750.25 (the "Brokered Financing Portion") and a non-brokered
private placement of 933,500 Units at a price of $0.75 per Unit for gross
proceeds of $700,125.00 (the "Non-Brokered Financing Portion"). Each
Unit consists of one common share of the Company (each, a "Share")
and one Share purchase warrant, which will entitle the holder to purchase one
additional Share for a period of two years from the closing of the private
placement at a price of $1.00 per Share during the first year and $1.25 per
Share during the second year. The Company anticipates a second closing under
the same terms. 
Wolverton Securities Ltd. (the "Agent") acted as the agent with
respect to the Brokered Financing Portion. The Agent and members of the selling
group also received warrants (the "Agent's Warrants") to
purchase an aggregate of 222,693 Shares of the Company at a price of $0.75 per
share for a period of 24 months and received a cash commission of $167,020. The
Agent also received a corporate finance fee of $25,000 and a member of the
selling group received an additional fee of $26,000. In connection with the
Non-Brokered Financing, the Company issued warrants to purchase an aggregate of
31,880 Shares on the same terms as the Agent's Warrants and paid a
finder's fee of $56,010 to four finders. 
All securities issued in the financing will be subject to a statutory hold
period expiring four months and one day after closing of the financing. None of
the securities issued in the financing have been registered under the United
States Securities Act of 1933, as amended (the "1933 Act"), and none
of them may be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the 1933 Act. This
press release shall not constitute an offer to sell or a solicitation of an
offer to buy nor shall there be any sale of the securities in any state where
such offer, solicitation, or sale would be unlawful. 
About RepliCel Life Sciences 
RepliCel is a clinical stage biopharmaceutical company focused on developing
autologous cell therapies that treat functional cellular deficits. RepliCel
Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon
injuries. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic
alopecia (pattern baldness). Shiseido Company, Limited has an exclusive
geographic license for RCH-01 in certain Asian countries including Japan, China
and South Korea. Both product candidates are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's own
healthy hair follicles to address specific cellular deficits. For additional
information please visit www.replicel.com. 
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange Inc.) accepts
responsibility for the adequacy or accuracy of this press release. 
This press release contains forward-looking information that involve various
risks and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on current
expectations involving a number of risks and uncertainties and are not
guarantees of future performance of RepliCel, such as the statement that
RepliCel is seeking additional financing. There are numerous risks and
uncertainties that could cause actual results and RepliCel's plans and
objectives to differ materially from those expressed in the forward-looking
information, including: (i) adverse market conditions; (ii) the inability of
RepliCel to complete the private placement at all or on the terms announced; or
(iii) the TSX Venture Exchange not approving further private placements. Actual
results and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on the dates they
are made and are expressly qualified in their entirety by this notice. Except
as required by law, RepliCel does not intend to update these forward-looking
statements. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
COMPANY CONTACT:
David M. Hall, Chief Executive Officer
Tammey George, Director of Communications
RepliCel Life Sciences
604-248-8696
or
INVESTOR CONTACTS:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
(858) 356-5932 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Trials 
SUBJECT:  STK 
-0-
-0- May/09/2014 19:59 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.